JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness

Completed · Not applicable

Conditions studied: Skin Smoothness of the Cheeks

In brief

This is a pivotal study to collect safety and effectiveness data on JUVÉDERM VOLITE™ XC for improvement in skin smoothness of the cheeks in order to support FDA product approval.

Key facts

Study ID: NCT03728309
Run by: Allergan
People needed: 209
Starts: 2018-11-09
Expected to finish: 2020-07-17
Last updated by the study team: 2022-12-19

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Ability to follow study instructions and likely to complete all required visits;
Written informed consent and data privacy consent have been obtained

You may not qualify if…

Has undergone tissue augmentation with dermal fillers including hyaluronic acid (HA), calcium hydroxylapatite, autologous fat, mesotherapy, or other cosmetic procedures (eg, face-lift, laser, photomodulation, intense pulsed light, radiofrequency, dermabrasion, chemical peel, or other ablative procedures) in the fact within 12 months before screening or is planning to undergo any such treatment during the study;
Has received any crosslinked HA filler in any anatomic area within 12 months of screening;
Has undergone treatment with botulinum toxin in the cheek area (including crow's feet) within 6 months of screening or is planning to undergo such treatment during the study;
Has ever received semi-permanent fillers or permanent facial implants (eg, poly-L-lactic acid, polymethylmethacrylate, silicone, expanded polytetrafuoroethylene) anywhere in the face or is planning to be implanted with any of these products at any time during the study;
Has facial tattoos, piercings, pigmentation, hair (ie, beard, mustache), or past trauma that would interfere with the visualization of the face for the effectiveness assessments;
Has undergone a dental procedure within 6 weeks before treatment or plans to undergo a dental procedure (other than prophylasix or dental fillings) during the course of the study;
Has tendency to develop hypertrophic scarring;
Has a history of allergy to lidocaine, HA products, and/or to gram-positive bacterial proteins as HA is produced by Streptococcus-type bacteria, or is planning to undergo desensitization therapy during the term of the study;
Has a history of anaphylactic shock;
Has current cutaneous inflammatory or infectious processes (eg, acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion on the face (injection may be delayed to allow subjects with a history of recurrent oral herpes to take prophylactic antiviral/herpes medication for 2 days);
Is on an ongoing regimen of anticoagulation therapy (eg, warfarin) or is known to have a coagulation disorder;
Is on an ongoing regimen of medications (eg, aspirin, ibuprofen) or other substances (eg, herbal supplements with garlic, ginkgo biloba, or ginseng) known to increase coagulation time within 10 days of undergoing study device injection (study device injection may be delayed as necessary to accommodate this 10-day washout period);
Has active autoimmune disease;
Has received any investigational product within 30 days before enrollment or is planning to participate in another investigation during the course of this study; - Has begun using any over-the-counter or prescription, oral or topical, anti-wrinkle products on the face within 30 days before enrollment or is planning to begin using such products during the study (subjects who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study);
Females who are pregnant, nursing, or planning a pregnancy during the study;
Is an employee (or a relative of an employee) of the principal investigator (PI)/evaluating investigator (EI)/treating investigator(TI)/site, Allergan, or representative of Allergan'
Has a condition or is in a situation which, in the TI's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Where it is running

Kathleen L. Behr M.D. Inc /ID# 236170 — Fresno, California, United States
Dermatology Research Associates /ID# 237649 — Los Angeles, California, United States
Ava MD — Santa Monica, California, United States
Art of Skin MD — Solana Beach, California, United States
Skin Research Institute LLC — Coral Gables, Florida, United States
Advanced Dermatology /ID# 234879 — Lincolnshire, Illinois, United States
Facial Plastic Surgery Center /ID# 234876 — Baltimore, Maryland, United States
Skincare Physicians /ID# 235383 — Chestnut Hill, Massachusetts, United States
Dermatology PartnersInc. /ID# 234946 — Wellesley, Massachusetts, United States
Dermatology and Laser Surgery Center of New York /ID# 234571 — New York, New York, United States
Dermatology Laser and Vein Specialists of Carolinas /ID# 236169 — Charlotte, North Carolina, United States
Clinical Research Center of the Carolinas /ID# 236488 — Charleston, South Carolina, United States
Dallas Center for Dermatology and Aesthetics /ID# 234452 — Dallas, Texas, United States
Jose Raul Montes Eyes & Facial Rejuvenation — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.